BioWorld Asia

Sep. 8, 2010

Pooled Phase III Data Underline Microplasmin's Efficacy in VMA

Clinicians Seek New Fund for Pan-European Trials

DBV Wins Grant for Phase II of Peanut Allergy Desensitizer

Other News To Note

Santhera, Ipsen Sign $181M Collaboration for Fipamezole

Shares in Santhera Pharmaceuticals AG rose more than 8 percent Friday on news of a European partnering deal with Ipsen Group SA, worth up to €141 million (US$181 million), for its Parkinson's drug Fipamezole. (BioWorld International) Read More

Forbion Closes $242M Fund for U.S., Israeli Investments

Today's news in brief

BioWorld

BioWorld briefs for Dec. 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 23, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...